Resources
Gain confidence in your clinical trials by exploring insights from industry-leading experts.
Our Products
(855) 338-8800
Gain confidence in your clinical trials by exploring insights from industry-leading experts.
Planning hybrid and decentralized clinical trials using sensor-driven data points? Check out our eBook, aligned with FDA guidance on DCTs, on considerations in selecting a digital health sensor partner.
Wiley.com | Clinic utilization time is significantly reduced with the KardiaMobile® 6L compared to traditional 12-lead ECG systems. This study published in Wiley highlights how KardiaMobile 6L minimizes the need for frequent conventional 12-lead use.
Beyond its traditional focus on cardiac-specific therapies, every investigational drug can potentially impact cardiac function. What if we expanded QT monitoring across various therapeutic areas?
At a QTc interval threshold of 500 milliseconds, the KardiaMobile 6-lead device had a high negative predictive value of 99.8% and was an effective triage test. This validation is pivotal for sponsors aiming to deliver quality data while alleviating common cardiac monitoring challenges.
QT determinations are essential in clinical trials, but collecting them is challenging. Discover how the KardiaMobile® 6L alleviates these challenges for more flexible and patient-centric trials.
PM360online.com | With treatment plans that require frequent ECG testing, patients with breast cancer are faced with even more challenges. Leveraging KardiaMobile® 6L, an IQVIA program alleviated the pains associated with traditional 12-lead systems.
StatNews.com | Hybrid and decentralized clinical trials are rapidly advancing. To ensure DCT success, mobile digital health technologies, like portable ECGs, are proving more necessary than ever.
PharmExec.com | Decentralized trials are known to have positive effects, but sponsors have concerns about how to monitor patients well. Remote patient monitoring (RPM) solutions, like those from AliveCor, are changing this paradigm. The benefits that decentralized trials offer patients and sponsors are evident. Yet, decentralized trials are still lacking.
JAMAnetwork.com | KardiaMobile® 6L transforms cardiac care in resource-limited settings. This study in JAMA highlights its accuracy in monitoring QT intervals, reducing standard 12-lead ECG dependency, and easing access to cardiac care.
JAMAnetwork.com | Patient-centric trials require accessible digital health technologies. A JAMA study explores the current state and aspired role of remote monitoring and data collection tools in oncology trials.
Wiley.com | Clinic utilization time is significantly reduced with the KardiaMobile® 6L compared to traditional 12-lead ECG systems. This study published in Wiley highlights how KardiaMobile 6L minimizes the need for frequent conventional 12-lead use.